Search results for "Tumor Suppressor Proteins"

showing 10 items of 123 documents

von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA Arrays

2003

Based on evidence that the von Hippel-Lindau (VHL) tumor suppressor protein is associated with polysomes and interacts with translation regulatory factors, we set out to investigate the potential influence of pVHL on protein translation. To this end, renal cell carcinoma (RCC) cells that either lacked pVHL or expressed pVHL through stable transfection were used to prepare RNA from cytosolic (unbound) and polysome-bound fractions. Hybridization of cDNA arrays using RNA from each fraction revealed a subset of transcripts whose abundance in polysomes decreased when pVHL function was restored. The tumor necrosis factor alpha (TNF-alpha) mRNA was identified as one of the transcripts that prefere…

Ubiquitin-Protein LigasesGene ExpressionEnzyme-Linked Immunosorbent AssayBiologyTransfectionurologic and male genital diseasesLigasesCytosolGenes ReporterPolysomeTumor Cells CulturedProtein biosynthesisHumansGenes Tumor SuppressorRNA Messenger3' Untranslated RegionsCarcinoma Renal CellMolecular BiologyOligonucleotide Array Sequence AnalysisReporter geneMessenger RNATumor Necrosis Factor-alphaThree prime untranslated regionGene Expression ProfilingTumor Suppressor ProteinsRNATranslation (biology)Cell BiologyTransfectionBlotting NorthernMolecular biologyfemale genital diseases and pregnancy complicationsGene Expression Regulation NeoplasticVon Hippel-Lindau Tumor Suppressor ProteinPolyribosomesProtein BiosynthesisMolecular and Cellular Biology
researchProduct

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

2008

Uveal melanoma is associated with a high mortality rate once metastases occur, with over >90% of metastatic patients dying within less than 1 year from metastases to the liver. The intraarterial hepatic (iah) administration of the alkylating agent fotemustine holds some promise with response rates of 36% and median survival of 15 months. Here, we investigated whether the DNA-repair-protein MGMT may be involved in the variability of response to fotemustine and temozolomide in uveal melanoma. Epigenetic inactivation of MGMT has been demonstrated to be a predictive marker for benefit from alkylating agent therapy in glioblastoma. We found a methylated MGMT promoter in 6% of liver metastases fr…

Uveal NeoplasmsCancer ResearchPathologymedicine.medical_specialtyProtein Array AnalysisAntineoplastic AgentsBiologyMetastasischemistry.chemical_compoundPredictive Value of TestsmedicineBiomarkers TumorHumansPromoter Regions GeneticneoplasmsDNA Modification MethylasesMelanomaTemozolomidePredictive markerTissue microarrayMelanomaTumor Suppressor ProteinsLiver NeoplasmsCancerDNA Methylationmedicine.diseaseImmunohistochemistrydigestive system diseasesNitrogen mustardDNA Repair EnzymesOncologychemistryCancer researchFotemustinemedicine.drugInternational journal of cancer
researchProduct

PML nuclear body-residing proteins sequentially associate with HPV genome after infectious nuclear delivery.

2019

Subnuclear promyelocytic leukemia (PML) nuclear bodies (NBs) are targeted by many DNA viruses after nuclear delivery. PML protein is essential for formation of PML NBs. Sp100 and Small Ubiquitin-Like Modifier (SUMO) are also permanently residing within PML NBs. Often, large DNA viruses disassemble and reorganize PML NBs to counteract their intrinsic antiviral activity and support establishment of infection. However, human papillomavirus (HPV) requires PML protein to retain incoming viral DNA in the nucleus for subsequent efficient transcription. In contrast, Sp100 was identified as a restriction factor for HPV. These findings suggested that PML NBs are important regulators of early stages o…

Viral DiseasesPhysiologyvirusesIntranuclear Inclusion BodiesPromyelocytic Leukemia ProteinVirus ReplicationBiochemistryAutoantigensImmune PhysiologyMedicine and Health SciencesCell Cycle and Cell DivisionNuclear proteinBiology (General)PapillomaviridaeStaining0303 health sciencesViral GenomicsImmune System ProteinsChromosome Biology030302 biochemistry & molecular biologyCell StainingTotal Cell CountingNuclear Proteinsvirus diseasesAntigens NuclearGenomicsCell biologymedicine.anatomical_structureInfectious DiseasesCapsidCell ProcessesViral GenomeCellular Structures and OrganellesIntranuclear SpaceResearch ArticleHuman Papillomavirus InfectionQH301-705.5UrologyImmunologyCell Enumeration TechniquesSUMO-1 ProteinSexually Transmitted DiseasesMitosisMicrobial GenomicsGenome ViralBiologyResearch and Analysis MethodsMicrobiologyVirusAntibodies03 medical and health sciencesPromyelocytic leukemia proteinVirologyNuclear BodiesmedicineGeneticsHumansVesiclesMolecular BiologyMitosisTranscription factor030304 developmental biologyCell NucleusGenitourinary InfectionsTumor Suppressor ProteinsBiology and Life SciencesProteinsCell BiologyRC581-607Cell nucleusViral replicationSpecimen Preparation and Treatmentbiology.proteinParasitologyCapsid ProteinsImmunologic diseases. AllergyTranscription FactorsPLoS Pathogens
researchProduct

Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours

2008

Aims:  To correlate the immunohistochemical detection of WWOX with histological measures and disease progression within the whole spectrum of urothelial bladder neoplasms. Methods and results:  One hundred and one patients with primary bladder tumours were retrospectively analysed. Immunohistochemically, a polyclonal antibody was utilized and the level of WWOX protein expression was analysed by using a combined score system based on intensity of the reaction and percentage of immunoreactive tumour cells. WWOX protein expression was consistently expressed in non-neoplastic urothelium, whereas a progressive loss of immunoreactivity was observed as tumour grade and stage increased (P < 0.05). …

WWOXAdultMalePathologymedicine.medical_specialtyHistologyCell CountBiologyArticlePathology and Forensic MedicinemedicineCarcinomaBiomarkers TumorHumansSurvival rateAgedRetrospective StudiesAged 80 and overCarcinoma Transitional CellPredictive markerUrinary bladderTumor Suppressor ProteinsCancerGeneral MedicineMiddle Agedmedicine.diseaseSquamous metaplasiaSurvival Ratemedicine.anatomical_structureUrinary Bladder NeoplasmsWW Domain-Containing OxidoreductaseSpainFemaleUrotheliumOxidoreductasesProgressive disease
researchProduct

WWOX-related encephalopathies: delineation of the phenotypical spectrum and emerging genotype-phenotype correlation

2014

International audience; BACKGROUND:Homozygous mutations in WWOX were reported in eight individuals of two families with autosomal recessive spinocerebellar ataxia type 12 and in two siblings with infantile epileptic encephalopathy (IEE), including one who deceased prior to DNA sampling.METHODS:By combining array comparative genomic hybridisation, targeted Sanger sequencing and next generation sequencing, we identified five further patients from four families with IEE due to biallelic alterations of WWOX.RESULTS:We identified eight deleterious WWOX alleles consisting in four deletions, a four base-pair frameshifting deletion, one missense and two nonsense mutations. Genotype-phenotype correl…

WWOXMicrocephaly[SDV]Life Sciences [q-bio]Nonsense mutationMutation MissenseBiology03 medical and health sciences0302 clinical medicineGeneticsmedicineHumansSpinocerebellar AtaxiasMissense mutationAlleleGenetics (clinical)infantile030304 developmental biologyGeneticsComparative Genomic Hybridization0303 health sciences[ SDV ] Life Sciences [q-bio]Tumor Suppressor ProteinsChromosomal fragile siteHigh-Throughput Nucleotide Sequencinggenotype/phenotype correlationsmedicine.diseaseNull allele3. Good healthPhenotypeWW Domain-Containing OxidoreductaseCodon Nonsenseintellectual disabilitySpinocerebellar ataxiaOxidoreductasesSpasms Infantilehigh throughput data mining030217 neurology & neurosurgeryJournal of Medical Genetics
researchProduct

Functional Assessment of Variants in the TSC1 and TSC2 Genes Identified in Individuals with Tuberous Sclerosis Complex

2011

The effects of missense changes and small in-frame deletions and insertions on protein function are not easy to predict, and the identification of such variants in individuals at risk of a genetic disease can complicate genetic counselling. One option is to perform functional tests to assess whether the variants affect protein function. We have used this strategy to characterize variants identified in the TSC1 and TSC2 genes in individuals with, or suspected of having, Tuberous Sclerosis Complex (TSC). Here we present an overview of our functional studies on 45 TSC1 and 107 TSC2 variants. Using a standardized protocol we classified 16 TSC1 variants and 70 TSC2 variants as pathogenic. In add…

congenital hereditary and neonatal diseases and abnormalitiesGenetic counselingtuberous sclerosis complexBiologyTuberous Sclerosis Complex 1 Protein03 medical and health sciencesTuberous sclerosis0302 clinical medicineTuberous SclerosisGenetic variationTuberous Sclerosis Complex 2 ProteinGeneticsmedicineMissense mutationHumansunclassified variantsGeneGenetics (clinical)Cells Cultured030304 developmental biologyGenetics0303 health sciencesModels GeneticTumor Suppressor ProteinsLife SciencesGenetic Variationmedicine.diseaseTSC23. Good healthnervous system diseasesTSC1medicine.anatomical_structureTSC1TSC2030217 neurology & neurosurgeryCommon disease-common variant
researchProduct

RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development

2012

The Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor whose inactivation is implicated in the development of many human cancers, including breast carcinomas. Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors. Here, we show that RASSF1A inhibits breast cancer growth in vivo, and suppresses estrogen receptor (ERα) expression and function. Reconstitution of RASSF1A in MCF7 cells led to decreased ERα levels and reduced sensitivity to estrogen (E2). Concomitantly, we observed decreased expression of Id1 as well as the E2-responsive gen…

endocrine systemCancer Researchmedicine.medical_specialtyCell SurvivalGene ExpressionEstrogen receptorApoptosisBreast NeoplasmsCell Cycle ProteinsMice SCIDBiologyMiceBreast cancerDownregulation and upregulationMice Inbred NODInternal medicineGeneticsmedicineAnimalsHumansFulvestrantMolecular BiologyCellular SenescenceCell ProliferationRegulation of gene expressionEstradiolFulvestrantTumor Suppressor ProteinsEstrogen AntagonistsEstrogen Receptor alphaCancerEstrogensCell Cycle Checkpointsmedicine.diseaseGene Expression Regulation NeoplasticEndocrinologyProteolysisMCF-7 CellsCancer researchFemaleEctopic expressionEstrogen receptor alphaNeoplasm TransplantationSignal Transductionmedicine.drugOncogene
researchProduct

Identification and characterization of a monoclonal antibody to the membrane fatty acid binding protein

1992

A monoclonal antibody to the rat liver membrane fatty acid binding protein (MFABP) was prepared by immunizing mice with purified MFABP isolated from solubilized rat liver plasma membrane proteins by oleate-agarose affinity chromatography technique. The monoclonal antibody K15/6 identified a single 40 kDa protein in rat liver plasma membranes with pI values of 8.5, 8.8 and 9.0, which is identical to the authentic MFABP, but clearly distinct from rat mitochondrial GOT. The antibody K15/6 selectively inhibited cellular influx as well as membrane binding of fatty acids, but not of cholesterol or vitamin E. The same antibody was used in immunofluorescence, ELISA and Western blot analysis to dete…

medicine.drug_classBlotting WesternImmunoblottingBiophysicsFluorescent Antibody TechniqueEnzyme-Linked Immunosorbent AssayNerve Tissue ProteinsFatty Acid-Binding ProteinsMonoclonal antibodyBiochemistryFatty acid-binding proteinCell LineMiceEndocrinologyAffinity chromatographymedicineAnimalsHumanschemistry.chemical_classificationMice Inbred BALB CbiologyMembrane transport proteinTumor Suppressor ProteinsBinding proteinCell MembraneFatty AcidsAntibodies MonoclonalFatty acidMolecular biologyNeoplasm ProteinsRatsLiverchemistryMembrane proteinBiochemistrybiology.proteinElectrophoresis Polyacrylamide GelAntibodyCarrier ProteinsFatty Acid-Binding Protein 7Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism
researchProduct

Novel missense mutation of the TP63 gene in a newborn with Hay-Wells/Ankyloblepharon-Ectodermal defects-Cleft lip/palate (AEC) syndrome: clinical rep…

2021

Abstract Introduction Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome, also known as Hay-Wells syndrome, is a rare genetic syndrome with ectodermal dysplasia. About 100 patients have been reported to date. It is associated to a heterozygous mutation of the tumor protein p63 (TP63) gene, located on chromosome 3q28. Typical clinical manifestations include: filiform ankyloblepharon adnatum (congenital adherence of the eyelids), ectodermal abnormalities (sparse and frizzy hair, skin defects, nail alterations, dental changes and hypohidrosis), and cleft lip/palate. Diagnostic suspicion is based on clinical signs and confirmed by genetic testing. Patient’s presentation We hereb…

medicine.medical_specialtyEctodermal dysplasiaHay–Wells syndromeCleft LipAnkyloblepharonMutation MissenseErythrodermaCase ReportEctodermal dysplasiaPediatricsRJ1-570TP63medicineMissense mutationHumansEye Abnormalitiesbusiness.industryTumor Suppressor ProteinsAEC syndromeInfant NewbornTumor protein p63 geneEyelidsmedicine.diseaseAnkyloblepharon-ectodermal defects-cleft lip/palate syndromeDermatologyCleft Palatemedicine.anatomical_structureHay-Wells syndromeScalpAgenesisFemaleAEC syndrome Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome Congenital skin disorders Ectodermal dysplasia Hay-Wells syndrome Tumor protein p63 genebusinessTranscription FactorsCongenital skin disordersItalian journal of pediatrics
researchProduct

A girl with an atypical form of ataxia telangiectasia and an additional de novo 3.14Mb microduplication in region 19q12

2011

A 9-year-old girl born to healthy parents showed manifestations suggestive of ataxia telangiectasia (AT), such as short stature, sudden short bouts of horizontal and rotary nystagmus, a weak and dysarthric voice, rolling gait, unstable posture, and atactic movements. She did not show several cardinal features typical of AT such as frequent, severe infections of the respiratory tract. In contrast, she showed symptoms not generally related to AT, including microcephaly, profound motor and mental retardation, small hands and feet, severely and progressively reduced muscle tone with slackly protruding abdomen and undue drooling, excess fat on her upper arms, and severe oligoarthritis. A cranial…

medicine.medical_specialtyMicrocephalyPathologyCell Cycle ProteinsAtaxia Telangiectasia Mutated ProteinsProtein Serine-Threonine KinasesBiologyShort statureAtaxia Telangiectasia Mutated ProteinsAtaxia TelangiectasiaInternal medicineChromosome DuplicationGene duplicationGeneticsmedicineHumansLymphocytesChildSalivaCerebellar hypoplasiaMetaphaseGenetics (clinical)Mental DisordersTumor Suppressor ProteinsGeneral Medicinemedicine.diseaseDNA-Binding ProteinsEndocrinologyChromosome InversionAtaxia-telangiectasiaChromosomal regionSpeech delayMicrocephalyFemalemedicine.symptomApoptosis Regulatory ProteinsChromosomes Human Pair 19DNA DamageEuropean Journal of Medical Genetics
researchProduct